Early Clinical Development of Lufotrelvir as a Potential Therapy for COVID-19
{{output}}
Lufotrelvir was designed as a first in class 3CL protease inhibitor to treat COVID-19. Development of lufotrelvir was challenged by its relatively poor stability due to its propensity to epimerize and degrade. Key elements of process development included impro... ...
